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Direct-acting oral anticoagulants (DOACs) have been approved for 
use in the United States since 2010.1-4 Their efficacy and safety 
have been demonstrated in large multinational trials for the preven-
tion and treatment of venous thromboembolism (VTE) and for the 
prevention of thrombosis in non-valvular atrial fibrillation (AF).5,6 
Compared to vitamin K antagonist therapy, DOACs offer the bene-
fits of limited drug interactions, standard dosing, lack of dietary con-
straints, and unnecessary therapeutic drug monitoring.7
While DOACs have changed the anticoagulation landscape, there 
is a paucity of data in specialty populations. Particularly, solid organ 
transplant recipients demonstrate unique pharmacokinetic consid-
erations regarding renal and hepatic function as well as drug-drug 
interactions.8 Transplant recipients also experience AF and VTE at 
a higher rate than the general population, making DOAC therapy an 
inciting treatment option for providers over traditional vitamin K an-
tagonist therapy despite the lack of prospective data.9,10 Currently, 
the data examining DOAC utilization in transplant recipients is lim-
ited to single-center retrospective assessments.8
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Abstract
The safety and efficacy of direct-acting oral anticoagulants (DOACs) and reversal 
strategies are not well established in the solid organ transplant population. This 
was a survey of pharmacists to assess DOAC and urgent reversal practices among 
adult transplant programs in the United States. A 27-question survey was distrib-
uted to members of transplant pharmacy organization listservs between 5/28/19 
and 6/30/19. A total of 115 responses were received from kidney (43.5%), heart 
(20.0%), lung (18.3%), liver (13.9%), and pancreas (4.4%) transplant programs. DOAC 
use prior to transplant was mostly prohibited in thoracic programs (77.3%) but more 
permissive in kidney transplant programs (64.0%). If permitted, apixaban (57.8%) was 
most preferred. At transplant surgery, reversal of DOAC was performed “as needed” 
(20.9%) or was not routine (18.3%). DOAC use post-transplant was more permissive 
(94.3%). A majority of responders follow FDA recommended dosing in the setting 
of	drug-drug	 interactions	 (51.1%).	Major	 factors	 influencing	DOAC	prescribing	de-
cisions included renal function, drug-drug interactions, and insurance. High clinical 
practice variability exists regarding DOAC utilization and urgent reversal strategies 
in pre-, peri-, and post-transplant stages. While more research is needed to refine the 
clinical landscape, many institutions are using DOAC therapy under the perception 
that they pose a similar risk of bleeding compared to a non-transplant population.
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Managing	DOAC	therapies	at	the	time	of	transplantation	can	be	
challenging. While guidance exists regarding DOAC therapy interrup-
tion in the context of elective surgery, these clinical recommendations 
were based on data excluding solid organ transplant recipients from 
analysis.11-13 Furthermore, anticoagulation reversal options are im-
portant to consider in order to appropriately manage patients in the 
setting of urgent surgeries or even adverse major bleeding events. 
The currently FDA-approved reversal agents, idarucizumab and an-
dexanet alfa, have primarily been utilized in the setting of acute major 
hemorrhage.14,15 Transplant patients often require urgent procedures 
or allograft biopsies in the setting of altered graft function and/or po-
tential drug-drug interactions, which can complicate the pharmacoki-
netics of DOAC therapy and reversal management.
Overall, limited data exist on the safe use of DOAC therapy after 
organ transplant, which has created significant clinical practice het-
erogeneity. In the advent of DOACs coming to the forefront of an-
ticoagulation modalities, transplant centers are faced with the need 
to reflect and even protocolize their approach to this class of medi-
cations. Therefore, the purpose of this transplant pharmacist survey 
study was to assess DOAC utilization and urgent reversal practices 
among adult transplant programs in the United States.
2  | MATERIAL S AND METHODS
A 27-question online survey was developed, consisting of 20 multi-
ple-choice and 7 open-ended questions (survey questions detailed 
in the Supplemental Information). The survey contained branch-
ing logic, depending on the allowance of DOAC therapy pre- and 
post-transplantation and focused on the practice patterns of DOAC 
therapy	in	the	pre-,	peri-,	and	post-transplant	phases.	Management	
and approach to reversal at the time of transplant surgery was also 
evaluated. All revisions were vetted across all investigators until a 
final survey instrument was agreed upon by the group. The survey 
was then pilot tested by external practitioners not involved with the 
study, and additional revisions were incorporated. The survey was 
completed using a Qualtrics® platform (Qualtrics, Provo, UT).
Surveys were distributed via the American Society of 
Transplantation Transplant Pharmacy Community of Practice list-
serv, the American College of Clinical Pharmacy Immunology/
Transplantation Practice and Research Network listserv, and the 
International Society of Heart and Lung Transplantation Scientific 
Council on Pharmacy and Pharmacology listserv. Pharmacist mem-
bers were invited to voluntarily submit a survey response per 
organ-specific program of their current practice. There was not in-
dividual contact with transplant programs. Each center was allowed 
to submit a single response per organ type. All allograft types were 
permitted to describe the national landscape and practice variation 
in DOAC therapy utilization.
The study was approved by the University of Illinois at Chicago 
Institutional Review Board, and the survey remained open between 
May	28,	2019	and	June	30,	2019.	All	surveys	that	were	more	than	
30% complete were included in the analysis.
3  | RESULTS
A total of 115 responses were received and 20 (17.4%) were par-
tial responses. Fifty (43.5%) were kidney, 23 (20.0%) were heart, 21 
(18.3%) were lung, 16 (13.9%) were liver, and 5 (4.4%) were SPK/
PAK/ pancreas alone. A total of 72 transplant centers provided re-
sponses for 115 organ-specific programs. These survey responses 
represent 34.1% of 211 adult transplant centers and 15% of 768 prac-
ticing adult organ programs identified via the Organ Procurement 
and Transplantation Network.16 Overall, a majority of programs 
performed at least 50 organ transplants per year (74/115, 64.3%). 
Renal transplant programs drove this response with 20/50 (40%) of 
responders reporting 101-200 kidneys and 16/50 (32%) performing 
over 200 kidneys in 2018. A majority of the liver transplant cent-
ers were high-volume with 8/16 (50%) of responders reporting >100 
liver transplants per year. Inversely, a majority of thoracic program 
responders reported having performed <50 transplants per year 
(27/44, 61.4%) within their respective organ. Consistencies between 
survey responses were maintained when compared between large 
and small kidney transplant programs. Summarized survey results 
are detailed in Table 1 with organ-specific data being included in 
Supplemental Information (Table S1).
3.1 | Pre-Transplant DOAC Utilization
Prior to transplant, 43/115 (37.4%) of the responders allow patients 
to remain on DOAC therapy. Thirty-two out of fifty (64.0%) kidney 
transplant programs allow patients to remain on DOAC therapy while 
on the transplant waitlist with 15/50 (30.0%) kidney transplant pro-
grams allowing it for candidates for planned living donor transplant. 
For liver transplantation, there is typically no consistent approach 
for allowing patients to remain on DOAC therapy while on the wait-
list (7/16, 43.8%), and 4/16 (25.0%) responded they continue DOAC 
therapy while on the waitlist. The majority of heart (18/23, 78.3%) 
and lung (16/21, 76.2%) transplant programs do not allow patients to 
remain on DOAC therapy while on the waitlist.
Apixaban (26/45, 57.8%) was the most preferred agent for waitlist 
transplant candidates, while 12/45 (26.7%) of responding programs 
had no preferred agent. Responders from abdominal transplant pro-
grams (23/36, 63.9%) preferred apixaban, while thoracic programs 
split between dabigatran (4/9, 44.4%) and apixaban (3/9, 33.3%). Of 
those with a preferred agent, 12/27 (44.4%) responded that they will 
switch to the preferred DOAC while the patient is on the transplant 
waitlist. When DOAC utilization was not allowed, warfarin was typ-
ically the preferred agent (36/49, 73.5%).
3.2 | Peri-Transplant DOAC Reversal
DOAC reversal was not common during transplant surgery. Of the 
115 responders, only 9 programs (7.8%) reported a routine use of 
DOAC reversal agents, of which 7 were thoracic organ transplant 
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TA B L E  1   Summarized DOAC Survey Results
Variable  
Total number of responsesa  115




Pancreas (SPK, PAK, pancreas alone) 5 (4.4)
Liver 16 (13.9)
Number of transplants per year, n (%)
<50 organs 41 (35.7)
50-100 organs 26 (22.6)
101-200 organs 30 (26.1)
>200 organs 18 (15.7)
Role of the Transplant Pharmacist (multiple options able to be selected), n (%)
Pharmacist evaluation/discussion prior to selection committee review and listing 98 (85.2)
Pharmacist evaluation/discussion prior to transplantation after listing 38 (33.0)
Pharmacist is not involved in management of DOAC therapy 13 (11.3)
Other role, not otherwise specified 9 (7.8)
Organ programs that allow for patients on the transplant waitlist to remain on DOAC therapy, n (%)  
Yes 28 (24.4)
No 49 (42.6)
Yes, only for living donor transplant candidates 15 (13.0)
No consistent approach within the program 23 (20.0)





No preferred agent 12/45 (26.7)
Organ Programs that allow for DOAC therapy post-transplant, n (%)
Yes 100/106 (94.3)
No 6/106 (5.7)
Factors influencing prescribing or recommending specific DOAC therapy post-transplant (multiple options able to be selected), n (%)
Patient preference 49/95 (51.6)
Insurance coverage 64/95 (67.4)
Patient renal function 75/95 (79.0)
Patient body habitus 24/95 (25.3)
Concomitant drug-drug interactions 74/95 (77.9)
Thrombophilia 9/95 (9.5)
Other, not otherwise specified 22/95 (23.2)
Perceived risk of DOAC use post-transplant (multiple options able to be selected), n (%)
Similar risk to non-transplant population 44 (38.3)
Increased risk for bleeding compared to non-transplant population 38 (33.0)
Limited data in the context of DOAC use in this population 74 (64.3)
Need to intensify immunosuppression drug monitoring for drug interactions 7 (6.1)
Other, not otherwise specified 12 (10.4)
aProportions were calculated based on 115 responders unless specified. 
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programs. Twenty-one (18.3%) do not routinely reverse DOAC 
therapy and 24 responders (20.9%) utilize reversal agents on an “as 
needed”	basis.	Most	of	the	responders	(53.0%)	reported	that	patients	
were not brought to transplant while maintained on DOAC therapy.
A total of 25 responders commented about DOAC-specific re-
versal strategies (dabigatran n = 8, apixaban n = 7, rivaroxaban n = 5, 
edoxaban n = 5). Idarucizumab (6/8, 75.0%) was the most routinely 
used agent for dabigatran reversal. Similarly, 14/17 (82.4%) respond-
ers report using the 4-factor prothrombin complex concentrate 
(4F-PCC) for reversal of factor Xa inhibitors. If the programs do not 
routinely use DOAC reversal, 15/93 (16.1%) responders report de-
laying or canceling transplantation due to inadequate time for hold-
ing DOAC therapy. This practice was less commonly observed in 
thoracic transplant programs 2/34 (5.9%) compared to kidney 10/40 
(25.0%), pancreas 1/5 (20.0%), or liver 2/14 (14.3%) transplant pro-
grams. Smaller kidney transplant programs (<100 transplants per 
year) reported delaying or canceling transplantation in the setting 
of DOAC therapy (5/10, 50%) compared to larger kidney transplant 
programs (25/30, 83.3%).
At the time of transplantation, 30/102 (29.4%) responders 
report using one or more type of laboratory monitoring tool to 
assess safety prior to transplant surgery. The most commonly 
used monitoring parameters were aPTT (13/30, 43.0%), PT/INR 
(11/30, 36.7%), and anti-Xa monitoring (10/30, 33.3%). Thoracic 
transplant programs (17/30, 56.7%) comprised the largest group 
using laboratory monitoring prior to transplant surgery relative to 
kidney (10/30, 33.3%), liver (2/30, 6.7%), or pancreas (1/30, 3.3%) 
programs.
3.3 | Post-Transplant DOAC Utilization
Out of 106 responses, 100 (94.3%) allow DOAC therapy in the post-
transplant setting. Time to initiation or re-initiation of DOAC after 
transplantation was not protocolized (37/90, 41.1%); furthermore, 
44/89 (49.4%) do not have a cutoff for CrCl threshold for DOAC 
initiation.
In the setting of drug-drug interactions, 45/88 (51.1%) do not de-
viate from the dosing contained within the prescribing information. 
Of the centers that reduce DOAC dosing outside of the FDA labeling 
information, 18/32 (56.3%) will reduce for one drug-drug interaction 
and 14/32 (43.8%) will consider DOAC dose reduction in the setting 
of two or more drug-drug interactions.
A total of 42/96 responders (43.8%) avoid DOAC use in the set-
ting of cyclosporine therapy, whereas 13/96 (13.5%) would reduce 
DOAC dose with concomitant use of cyclosporine. For patients on 
tacrolimus,	76/103	(73.8%)	do	not	adjust	DOAC	dose.	Many	cen-
ters allowed concomitant aspirin utilization with DOAC therapy 
(27/33, 81.8%). Similarly, a majority of patients on DOAC ther-
apy are also permitted to be on non-aspirin anti-platelet therapy 
(21/33, 63.6%).
Patient renal function (75/95, 79.0%), concomitant drug-drug 
interactions (74/95, 77.9%), and patient insurance coverage (64/95, 
67.4%) were major factors that influenced prescribing decisions re-
garding DOAC therapy.
3.4 | Role of the Transplant Pharmacist
A total of 102/115 (88.7%) responders stated that a transplant phar-
macist is involved in the management of DOAC utilization prior to 
transplant and during waitlist maintenance. Transplant pharmacists 
are frequently involved in the evaluation and discussion of the man-
agement of DOAC therapy prior to transplant and listing (98/115, 
85.2%). Fewer pharmacists (38/115, 33.0%) are involved in the 
DOAC management of patients on the transplant waitlist.
While a majority of pharmacist responders (64.3%) acknowledge 
that transplant-specific data on DOAC use are lacking, opinions on 
perceived bleeding risks of DOAC in the transplant population were 
split between similar (38.3%) vs increased (33.0%) compared to the 
non-transplant population.
4  | DISCUSSION
Solid organ transplant recipients are more likely to require antico-
agulation for either AF or VTE comparatively to the general popula-
tion.9,10 However, no controlled trials exist investigating DOAC use 
in solid organ transplant recipients. In addition, there is significant 
variability in the reported drug-drug interactions and correspond-
ing recommendations for the DOAC dose adjustments.8 As such, 
health care providers need to make treatment decisions based on 
limited data from observational cohorts and individual practice ex-
periences.8,17 This is the first study to characterize the current use 
of DOAC therapy and reversal strategies in solid organ transplant 
programs across the United States.
The results of our survey highlight a lack of uniformity regard-
ing DOAC therapy in the pre-, peri-, and post-transplant phases of 
care. In the pre-transplant phase, 37.4% of responders allow pa-
tients to remain on a DOAC while on the waitlist. Kidney transplant 
programs predominately drive this response, as 77% of thoracic 
programs do not allow DOAC use while on the waitlist. For those 
centers allowing DOAC use while on the waitlist, apixaban is the 
preferred agent.
This preference is likely based on the pharmacokinetic proper-
ties of the DOACs, as apixaban is less reliant on kidneys for clear-
ance and may be utilized for patients with severe renal impairment 
or dialysis.1 Rivaroxaban does have significant renal clearance, in-
creasing drug exposure up to 64% when patients with severe renal 
impairment were compared to healthy volunteers.4 However, regis-
try data have shown a lower rate of stroke and systemic embolism 
with rivaroxaban with no difference in bleeding when compared to 
warfarin in patients with renal impairment.18 Dabigatran is primarily 
eliminated via the kidneys and generally not recommended for use in 
patients with renal insufficiency.2 Table 2 highlights the pharmacoki-
netic differences of DOAC agents.
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Peri-operatively, only 8% of programs report routinely reversing 
DOACs prior to transplant. Consistent with expectations, reversal of 
dabigatran has been primarily with idarucizumab (75% of respond-
ers), and 4F-PCC has been utilized for factor Xa inhibitors. None of 
our survey responders report the use of andexanet alfa, as the FDA 
did not approve full commercial launch of this agent until January 
2019 and the product was not widely distributed at the time of the 
survey. Small case series have described idarucizumab for dabiga-
tran reversal in transplant recipients.19-21 However, no data exists 
for andexanet alfa, in the reversal of apixaban or rivaroxaban in a 
transplant population.
Non-specific reversal agents, predominantly 4F-PCC, were 
reported by programs necessitating factor Xa inhibitor reversal. 
However, neither 4F-PCC nor activated prothrombin complex con-
centrate (aPCC) has FDA-approved indications for DOAC rever-
sal.22,23 Nevertheless, these observed reversal practices are in line 
with recent recommendations from The Anticoagulation Forum 
which recommend either idarucizumab or aPCC for dabigatran re-
versal and andexanet alfa or 4F-PCC for factor Xa inhibitor reversal, 
depending on the availability of selected specific reversal agent.13 
While studies have demonstrated that both 4F-PCC and aPCC are 
non-specific options for DOAC reversal, there is no data within solid 
organ transplant or comparative data to idarucizumab or andexa-
net alfa at this time. Table 3 details currently available DOAC rever-
sal options.
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CrCl 15 - 30 mL/
min: 30 mg PO 
daily
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Other indications: Avoid with 











Pugh B and C): 
Avoid use
Child-Pugh B or C or any degree of 
hepatic coagulopathy: Avoid use
CrCl exclusion in 
clinical trials
<25 mL/min <30 mL/min <30 mL/min <30 mL/min
Renal excretion 27% 80% 50% 36%
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Furthermore, 69.5% of responders reported not using laboratory 
monitoring (eg, PT, aPTT, thromboelastometry/rotational throm-
boelastometry) to assess safety prior to undergoing transplant. This 
finding matches the poor performance of these tests to accurately 
predict the degree of anticoagulation present.11 Interestingly, 16% 
of responders report the cancelation of transplant surgery due to 
bleeding concerns at the time of transplantation. This may reflect 
the inability to utilize more specific quantitative measures such as 
dilute thrombin time or ecarin clotting time for dabigatran or cali-
brated anti-factor Xa levels.11
While concerns persist around the safety of DOACs before 
and at the time of transplant surgery, nearly all responders (94%) 
reported using a DOAC in the post-transplant setting, suggesting 
that these agents are viewed similarly to warfarin therapy when 
chronic oral anticoagulation therapy is necessary after transplant. 
The majority of responders (51%) follow the FDA prescribing infor-
mation for dose adjustments, but of those that do not, 97% of re-
sponders make empiric dose adjustments for drug-drug interactions. 
Continued assessment for dose adjustments is paramount to DOACs 
in post-transplant patients. Lichvar et al found that 60% of patients 
had empiric DOAC dose reduction for known drug-drug interac-
tions, and 46% of patients who did not have empiric dose adjustment 
required DOAC dose adjustment while on therapy due to changes in 
renal function.17 These findings highlight that while therapeutic drug 
monitoring is not needed, close follow-up is necessary to ensure safe 
clinical utilization of DOAC therapy.
There is a critical role for the transplant pharmacotherapy spe-
cialist in the use of DOACs in this patient population. Eighty-five 
percent of pharmacists responded that they participate in the eval-
uation or discussion of patients on DOACs in the pre-transplant pe-
riod. Pharmacist involvement in outpatient DOAC management leads 
to improved appropriate DOAC dosing and medication adherence, 
highlighting the role of pharmacist monitoring in these patients.24
Nearly half (43.8%) of respondents avoid DOACs concomitantly 
with cyclosporine driven predominantly by kidney transplant pro-
grams; whereas, 13.5% reduce the dose empirically with cyclospo-
rine. The hesitancy to utilize cyclosporine in conjunction with DOACs 
stems from a case series describing higher rivaroxaban trough con-
centrations in those patients on cyclosporine (131.7 ± 119.5 ng/
mL) versus those patients on tacrolimus (20.3 ± 14.4 ng/mL).25 
Remarkably, the mean trough concentration for rivaroxaban in those 
patients on concurrent cyclosporine was higher than the reported 
reference range for trough concentrations for rivaroxaban (6-87 ng/
mL); moreover, this was in the setting of relatively low cyclosporine 
trough concentrations (69 ± 41 ng/mL).25 Therefore, the rivarox-
aban-cyclosporine interaction may be clinically more relevant com-
pared to rivaroxaban-tacrolimus.
Eighty-two percent of responders reported they allow concom-
itant aspirin and 64% reported use with concomitant non-aspirin 
anti-platelet agents in combination with DOACs. The use of an-
ti-platelet agents concomitantly with DOACs is a hot topic as pa-
tients with multiple comorbidities and indications for anti-platelet 
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four registration trials for dabigatran, rivaroxaban, apixaban, and 
edoxaban in AF failed to demonstrate a difference in major bleeding 
in patients who received single anti-platelet therapy with either a 
DOAC or warfarin.27 However, registry data from Canada were able 
to demonstrate a lower rate of major bleeding, with the exception 
of gastrointestinal bleeding, for those patients utilizing a single an-
ti-platelet plus DOACs versus warfarin.28 Clinicians should be atten-
tive to the potential increasing risk of bleeding for those patients 
utilizing single or dual anti-platelet therapy in combination with 
DOAC therapy versus DOAC alone.
A significant strength of our study is that this was an all phar-
macist-based survey that allowed for consistent interrater variabil-
ity. Additionally, this is the first study of its kind to describe DOAC 
clinical practice trends across transplant centers within the United 
States. In this way, there is shared knowledge regarding the ap-
proach to DOAC therapy across the specialty. This may encourage 
institutions to reflect on their approach to novel anticoagulation and 
promote others to share their experiences through peer-reviewed 
publications or abstracts.
There are several limitations with this study. As with any volun-
teer survey, there is a potential selection bias including only those 
centers that feel strongly (either positively or negatively) about 
DOAC use in transplant candidates or recipients, which could have 
influenced the findings. Although the diversity in the responses 
based on center volume, location, and organ discipline for each 
responder ameliorate this bias concern. Second, the response rate 
for this survey was 34.1%, which is low considering the number 
of institutions within the United States and the diversity of organ 
programs represented at each center. However, previous literature 
has reported an average rate of 39.6% for internet-based surveys.29 
The survey was distributed to only transplant pharmacists; however, 
other members of the transplant multidisciplinary team may have 
opinions that differ from the transplant pharmacist completing the 
survey. Despite this, the transplant pharmacists are likely to be in-
volved with or familiar with DOAC management at their respective 
institutions as the pharmacotherapy experts. Finally, no rates of VTE 
or bleeding were collected in our survey; therefore, we are unable to 
links variation in practice patterns to clinical outcomes. However, we 
felt that the inclusion of clinical outcomes may have decreased the 
survey response rate substantially and limited our ability to under-
stand the various practice using DOACs nationally.
5  | CONCLUSIONS
In conclusion, this all pharmacist-based survey evaluated the prac-
tice patterns of DOAC therapy in the pre-, peri-, and post-transplant 
phases in solid organ transplant recipients. There was a high rate 
of variability in DOAC management practices. The majority of cent-
ers do not allow DOAC use while on the waitlist or have a protocol 
for reversal at the time of transplant surgery. Nearly, all centers re-
ported utilizing the DOACs in the post-transplant phase, with the 
majority following the recommendations from the package insert 
regarding dose adjustments for end organ function and drug-drug 
interactions. DOAC use post-transplant needs to be evaluated in 
controlled studies to further elucidate the purported perils in this 
high-risk patient population.
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